|Bid||1.0400 x 39400|
|Ask||1.0600 x 3000|
|Day's Range||1.0100 - 1.1450|
|52 Week Range||0.9100 - 4.0000|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2021 - Aug. 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.05|
The big shareholder groups in Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ:CRBP ) have power over the company...
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through business development continues to be a priorityCash and investments on hand of $114M provides projected runway into first quarter of 2024 Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today prov